Carisma Therapeutics Inc.

CARISMA Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to CT-0508 for the Treatment of Patients with Solid Tumors

September 22, 2021 at 6:01 a.m.

PHILADELPHIA, Sept. 22, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that that the U.S. Food and Drug Administration...

CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer

September 23, 2021 at 5:59 a.m.

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Richard Morris has been appointed Chief...

CARISMA Therapeutics to Present Data at The American Society of Gene & Cell Therapy 24th Annual Meeting

September 23, 2021 at 6:13 a.m.

PHILADELPHIA, April 28, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation...

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

September 23, 2021 at 6:34 a.m.

PHILADELPHIA, April 26, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has established a multi-year scientific collaboration...

All Stories